Filed in archive
Research
, Treatment
by Gloria Gamat on July 11, 2007
Such were the findings of a 20-plus-year University of Pittsburgh School of Medicine-led study recently reported in the Journal of the American Medical Association:
The multi-center observational study of 4,905 adults with rheumatoid arthritis (RA) found that relative risk progressively declined by as much as 77 percent after four years of treatment with HCQ, a common antimalarial medication that also is used for rheumatoid arthritis and other autoimmune disorders.
That's right. HCQ is a common antimalarial drug as well.
Also, another interesting finding in this study is that in those arthritis patients taking HCQ but developed diabetes were less likely to need blood sugar-lowering medication to manage their diabetes - ultimately suggesting that HCQ can be useful as a preventive therapy for people with prediabetes.
Results show that HCQ's association with reduction in diabetes risk is comparable or superior to that of a number of other drugs studied in clinical trials for diabetes prevention and treatment, including rosiglitazone, hormones, metformin, acarbose and ramipril.
Find more details from the full report.
[Photo Credit: LUHS]
Tags:
hydroxychloroquine
rheumatoid
arthritis
malaria
drug
diabetes
rheumatoid+arthritis
arthritis+anti
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/80367
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Hydroxychloroquine (HCQ): Anti-malarial, Anti-Rheumatoid Arthritis, Now Anti-Diabetes?:
|
Rating: 9.67 out of 3 vote(s) cast.
|
Response from:
UniversalUpdate.com
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
